Cyst Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Imaging and Pathology

Grenacher, Lars; Strauss, Albert; Bergmann, Frank; Birdsey, Matthew; Mayerle, Julia

doi:10.1159/000375254

Cited by 8 publications

(9 citation statements)

References 50 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 36 ] As 18-FDG PET is not routinely performed for its high cost and radiation, the decision of whether to do a surgery or not remains challenging. [ 41 ] Studies of molecular markers were also reported recently. It is reported that the sensitivity and specificity of KRAS mutations analysis in differentiating malignancy from benign PCNs were 0.59 (95% CI: 0.46–0.71) and 0.78(0.71–0.85), respectively.…”

Section: Discussionmentioning

confidence: 99%

Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis

Cao

Gao

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

BackgroundUsing serum carbohydrate antigen 19–9 (CA 19–9) in discriminating between benign and malignant pancreatic disease remains controversial. We aim to evaluate the diagnostic value of serum CA 19–9 in predicting malignant pancreatic cystic lesions.MethodsEligible studies were identified through searching MEDLINE and EMBASE prior to March 2016. Studies were assessed for quality using the Quality Assessment for Studies of Diagnostic Accuracy, 2nd version (QUADAS-2). Pooled sensitivity and specificity with 95% confidence interval (CI) were calculated using random-effects models. Summary receiver operator characteristic (SROC) curves and the area under curve (AUC) were performed.ResultsA total of thirteen studies including 1437 patients were enrolled in this meta-analysis. The pooled sensitivity and specificity were 0.47(95% CI: 0.35–0.59), and 0.88(95% CI: 0.86–0.91), respectively, and the AUC was 0.87(95% CI, 0.84–0.90). Meta-regression analysis showed that sample size, region and reference standards were not the main sources of heterogeneity.ConclusionsSerum CA 19–9 has satisfying pooled specificity while poor pooled sensitivity for discriminating benign from malignant PCNs. It deserves to be widely used as complementary to other clinical diagnostic methods.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis

Cao

Gao

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Every pancreatic cyst larger than 10 mm should be evaluated either with computed tomography (CT) or with gadolinium-enhanced magnetic resonance imaging (MRI) accompanied by magnetic resonance cholangiopancreatography (MRCP) [10,39]. MRI/MRCP is the imaging method of choice due to its greater sensitivity in detecting pancreatic neoplasms.…”

Section: Diagnostic Imagingmentioning

confidence: 99%

“…Interestingly, a high ratio of these neoplasms (about 39%) is multifocal over the pancreas [3,9]. In addition, the development of IPMNs has been related to genetic syndromes, such as familial adenomatous polyposis (FAP), BRCA2-associated hereditary breast cancer, Peutz-Jeghers syndrome, Von Hippel-Lindau (VHL) syndrome, familial pancreatic cancer (FPC), and various autoimmune diseases [2,10]. A medical history of diabetes mellitus (DM) or family history of pancreatic ductal adenocarcinoma (PDAC) has also been related to IP-MNs development [11].…”

Section: Introductionmentioning

confidence: 99%

Pancreatic Intraductal Papillary Mucinous Neoplasms: A Narrative Review

Paramythiotis

Karlafti²,

Fotiadou³

et al. 2023

AML

View full text Add to dashboard Cite

Introduction: Intraductal papillary mucinous neoplasms (IPMNs) are the most frequent cystic pancreatic neoplasm. They derive from the main pancreatic duct or branch ducts. Aim: This narrative review aims to present and compare the current guidelines on the management of IPMNs. Materials and methods: We reviewed the most important scientific literature on the management of IPMNs. Discussion: The clinical presentation of IPMNs is usually non-specific; common symptoms are abdominal pain, weight loss, and jaundice. There are no sex differences, and the incidence increases with age. It is considered a premalignant lesion associated with synchronous or metachronous carcinomas. Multifocal sites within the pancreas and the presence of solid components, like mural nodules, are predictive factors for developing malignancy. Magnetic resonance imaging (MRI) is the imaging technique of choice. However, computed tomography (CT) and endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) can also contribute to the diagnosis. Resection is the optimal treatment for IPMNs that arise from the main duct, while several indications are suggested for the surgery on IPMNs of branch ducts. Conclusion: The decision on surgery is not always a simple task and should be based on high-risk features of the neoplasm. In any case, re-examination and follow-up are highly recommended.

show abstract

“…IPMNs less than 10 mm in size may still confer a risk of malignancy transformation [ 14 ]. Although size is an unreliable predictor of malignancy, patients with large lesions should be monitored even more closely [ 15 ].…”

Section: Reviewmentioning

confidence: 99%

Intraductal Papillary Mucinous Neoplasm of the Pancreas: Understanding the Basics and Beyond

Weissman

Thaker

Zeffren

et al. 2019

Cureus

View full text Add to dashboard Cite

Intraductal papillary mucinous neoplasm (IPMN) is a benign cystic lesion that grows in the pancreatic ductal system. While the risk for undergoing malignant transformation is dependent on a number of factors, the risk is certainly present, differentiating it from other cystic lesions of the pancreas. Additionally, IMPN is to be starkly contrasted with adenocarcinoma of the pancreas, which is by nature malignant. There are numerous ways to detect IPMN, which is helpful, as a patient may be initially asymptomatic at presentation. Prognosis varies depending upon the malignant potential of the lesion at hand. Surgical resection is the mainstay of treatment in patients with a high probability of malignancy potential. What once was a very confusing diagnosis is now becoming defined based on new literature. The goal of this manuscript is to compile the literature on IPMNs in a clear and precise way as to educate clinicians as to the nature of this increasingly prevalent disease.

show abstract

Cyst Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Imaging and Pathology

Cited by 8 publications

References 50 publications

Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis

Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis

Pancreatic Intraductal Papillary Mucinous Neoplasms: A Narrative Review

Intraductal Papillary Mucinous Neoplasm of the Pancreas: Understanding the Basics and Beyond

Contact Info

Product

Resources

About